Dr Hogg
Food and Nutrition
GAMMADELTA
Ukraine
Biography
Dr Hogg joined GammaDelta Therapeutics Limited in 2017 from Kesios Therapeutics Limited, where he was Chief Operating Officer. Previously (2011-2015), Dayle was an investment manager at Touchstone Innovations (formerly Imperial Innovations) where he was part of the team focusing on investments in therapeutics and medical device businesses. Dayle has previously led or participated in a number of Seed and Series A investments for therapeutics businesses on behalf of Touchstone Innovations. Prior to joining Touchtone Innovations Dayle has worked in commercial roles within the biotechnology sector and has more than 15 years’ operational experience of drug discovery and development across multiple therapeutic fields. Dayle was previously Commercial Vice President of Lectus Therapeutics Limited where he was responsible for the closure of a number of licensing and divestment transactions including a licensing and acquisition transaction with UCB. Dayle has DPhil in Pharmacology from the University of Oxford and a degree in Pharmacology from the University of Leeds. Dayle is also a current non-executive director of Kesios Therapeutics Limited.
Research Interest
Dr Hogg joined GammaDelta Therapeutics Limited in 2017 from Kesios Therapeutics Limited, where he was Chief Operating Officer. Previously (2011-2015), Dayle was an investment manager at Touchstone Innovations (formerly Imperial Innovations) where he was part of the team focusing on investments in therapeutics and medical device businesses. Dayle has previously led or participated in a number of Seed and Series A investments for therapeutics businesses on behalf of Touchstone Innovations. Prior to joining Touchtone Innovations Dayle has worked in commercial roles within the biotechnology sector and has more than 15 years’ operational experience of drug discovery and development across multiple therapeutic fields. Dayle was previously Commercial Vice President of Lectus Therapeutics Limited where he was responsible for the closure of a number of licensing and divestment transactions including a licensing and acquisition transaction with UCB. Dayle has DPhil in Pharmacology from the University of Oxford and a degree in Pharmacology from the University of Leeds. Dayle is also a current non-executive director of Kesios Therapeutics Limited.
